Sclerosis: Clinical Trials

4 trials for Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 31Completed 1

Follow Sclerosis: new trials by email Literature Review of Sclerosis trials Research Report on Sclerosis

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
Simtuzumab, Placebo - Primary Sclerosing Cholangitis (PSC)
Phase 2CompletedGilead Sciences2352013-03-042019-10-22
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
LY2127399, Placebo - Relapsing-Remitting Multiple Sclerosis
Phase 2CompletedEli Lilly and Company2452009-04-012018-11-15
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
Levetiracetam - Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Phase 2CompletedDuke University202006-05-012013-06-19
Scleroderma: Cyclophosphamide or Transplantation
mHSCT, cyclophosphamide - Scleroderma, Systemic, Sclerosis
Phase 2 / Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)752005-06-012023-04-12

Narrower conditions

Amyotrophic Lateral Sclerosis (1)  ·  Autoimmune Diseases (1)  ·  Cholangitis, Sclerosing (1)  ·  Liver Cirrhosis (1)  ·  Liver Diseases (1)  ·  Motor Neuron Disease (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Muscle Cramp (1)  ·  Muscle Spasticity (1)  ·  Muscular Atrophy, Spinal (1)  ·  Recurrence (1)  ·  Scleroderma, Systemic (1)

Broader conditions

Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Immune System Diseases (2)  ·  Nervous System Diseases (2)  ·  Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Bile Duct Diseases (1)  ·  Biliary Tract Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cholangitis (1)  ·  Connective Tissue Diseases (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Digestive System Diseases (1)  ·  Disease Attributes (1)

Interventions

BID protein, human (1)  ·  Cyclophosphamide (1)  ·  Levetiracetam (1)  ·  simtuzumab (1)  ·  tabalumab (1)

Sponsors

Duke University (1)  ·  Eli Lilly and Company (1)  ·  Gilead Sciences (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

United States (4)  ·  Canada (2)  ·  Germany (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Daniel E. Furst, MD (1)  ·  Keith M. Sullivan, MD (1)  ·  Leslie J. Crofford, MD (1)  ·  Maureen D. Mayes, MD, MPH (1)  ·  Peter A. McSweeney, MD (1)  ·  Richard A. Nash, MD (1)  ·  Richard S Bedlack, MD, PhD (1)

Results publications

PMID 20708086, PMID 20800376, PMID 23418384, PMID 28602891, PMID 29298160, PMID 30153359, PMID 33131208, PMID 34533286, PMID 35108379, PMID 35904231, PMID 38967589, PMID 39996122